University of Michigan Rheumatic Diseases Research Core Center

描述（由申请人提供）： 密歇根大学提议更新其风湿病研究核心中心（UM-RDCC）的资金。UM-RDCC是一个基础广泛的努力，涉及大约80名教师，他们寻求应用广泛的研究技能，背景和方法来调查风湿性疾病的病因和发病机制中的基本问题，并为新疗法开发科学基础。UM-RDCC将促进研究人员在研究实力和兴趣的主题领域之间的合作，例如创新疗法的开发和测试，风湿性疾病的免疫机制分析以及器官靶向炎症和组织重塑途径的研究。UM-RDCC还将促进与临床研究计划相关的疾病重点实验室和转化研究。该中心的活动将得到六个生物医学核心设施的支持，包括流式细胞术，杂交，载体，转基因动物，蛋白质结构和微阵列。提出了三个试点和可行性项目，其中两个是由最近招募到UMRDCC，其重点是炎症性关节炎的发病机制的新教师领导。第三个试点和可行性项目由一位经验丰富的皮肤病学研究者领导，他将机械地研究治疗硬皮病的高度创新方法。UM-RDCC及其行政单位将由大卫A领导。福克斯医学博士他在管理基础广泛的NIAMS资助的中心项目方面有15年的经验。Rory Marks医学博士流变学副教授被提议继续担任UMRDCC副主任，特别负责监督生物医学核心。该中心的行政团队将由一个执行委员会，一个内部咨询委员会和两个外部科学顾问，迈克尔布伦纳博士和迈克尔霍勒斯协助。UM-RDCC旨在最大限度地利用密歇根大学的人才和资源，专注于风湿性疾病的研究。该中心的领导层将保持UM-RDCC的基础和临床前研究活动与密歇根大学风湿病临床研究的密切联系，以最大限度地发挥UM-RDCC发现对风湿病患者健康的影响。

DESCRIPTION (provided by applicant): The University of Michigan proposes to renew funding for its Rheumatic Diseases Research Core Center (UM-RDCC). The UM-RDCC is a broadly based effort involving approximately eighty faculty, who seek to apply a broad range of research skills, backgrounds, and approaches to investigation of fundamental issues in the etiology and pathogenesis of rheumatic diseases and in development of a scientific basis for novel therapeutics. The UM-RDCC will foster collaborations between investigators in thematic areas of research strength and interest, such as development and testing of innovative therapeutics, analysis of immune mechanisms in rheumatic diseases and investigation of organ-targeted inflammatory and tissue remodeling pathways. The UM-RDCC will also foster disease focused laboratory and translational research linked to clinical research programs. Activities in the Center will be supported by six Biomedical Core Facilities, including Flow Cytometry, Hybridoma, Vector, Transgenic Animal, Protein Structure, and Microarray. Three Pilot and Feasibility Projects are proposed, two of which are led by new faculty recently recruited to the UMRDCC, whose focus is the pathogenesis of inflammatory arthritis. The third Pilot and Feasibility Project is led by an experienced dermatology investigator who will mechanistically investigate a highly innovative approach to treating scleroderma. The UM-RDCC and its administrative unit will be directed by David A. Fox, M.D., who has fifteen years of experience in administration of broadly based, NIAMS-funded center programs. Rory Marks, M.D., Associate Professor of Rheumatology is proposed to continue as the UMRDCC Associate Director, with special responsibilities for supervision of the biomedical cores. The Center's administrative team will be assisted by an Executive Committee, an Internal Advisory Committee, and two External Scientific Advisors, Drs. Michael Brenner and Michael Holers. The UM-RDCC is constructed to maximally engage the talents and resources of the University of Michigan to focus on research in the rheumatic diseases. The Center leadership will maintain close links between the basic and pre-clinical research activities of the UM-RDCC and expanding clinical investigation in the rheumatic diseases at the University of Michigan, so as to maximize the impact of UM-RDCC discoveries on the health of patients with rheumatic diseases.